

Anke C Reinacher-Schick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9844858/publications.pdf>

Version: 2024-02-01

55
papers

979
citations

687363

13
h-index

454955

30
g-index

61
all docs

61
docs citations

61
times ranked

1435
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1355-1369.	10.7	228
2	FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). <i>Journal of Clinical Oncology</i> , 2019, 37, 3401-3411.	1.6	132
3	Blood-based detection of <i>RAS</i> mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based <i>RAS</i> testing. <i>Molecular Oncology</i> , 2017, 11, 208-219.	4.6	125
4	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3929-3939.	1.6	66
5	Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). <i>Journal of Clinical Oncology</i> , 2022, 40, 72-82.	1.6	42
6	Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4008-4008.	1.6	39
7	Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 339-341.	3.5	34
8	Severe refractory CIDP: a case series of 10 patients treated with bortezomib. <i>Journal of Neurology</i> , 2017, 264, 2010-2020.	3.6	33
9	Amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e285.	6.0	19
10	Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. <i>European Journal of Cancer</i> , 2018, 101, 105-113.	2.8	19
11	Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3503-3503.	1.6	17
12	Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated <i>ERBB2</i> -Positive Esophagogastric Adenocarcinoma. <i>JAMA Oncology</i> , 0, , .	7.1	17
13	FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, E9-E12.	1.4	16
14	POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline <i>BRCA1/2</i> mutation (<i>gBRCA</i> m).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4152-TPS4152.	1.6	15
15	Multiple cerebral infarctions in a young patient with heroin-induced hypereosinophilic syndrome. <i>Journal of the Neurological Sciences</i> , 2015, 356, 193-195.	0.6	14
16	mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3509-3509.	1.6	14
17	Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial. <i>Frontiers in Oncology</i> , 2018, 8, 474.	2.8	13
18	Label-free, automated classification of microsatellite status in colorectal cancer by infrared imaging. <i>Scientific Reports</i> , 2020, 10, 10161.	3.3	13

#	ARTICLE	IF	CITATIONS
19	What does physicians' clinical expertise contribute to oncologic decision-making? A qualitative interview study. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 180-186.	1.8	12
20	Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy. <i>Journal of Neuroimaging</i> , 2019, 29, 133-139.	2.0	11
21	Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial. <i>Clinical Chemistry</i> , 2020, 66, 1510-1520.	3.2	11
22	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA4-LBA4.	1.6	11
23	Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer. <i>Visceral Medicine</i> , 2019, 35, 387-391.	1.3	10
24	NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313) Safety interim analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4128-4128.	1.6	8
25	Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Updated final results of the randomized phase II AIO-NEONAX trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4133-4133.	1.6	8
26	Low Serological Prevalence of SARS-CoV-2 Antibodies in Cancer Patients at a German University Oncology Center. <i>Oncology Research and Treatment</i> , 2022, 45, 112-117.	1.2	7
27	Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3511-3511.	1.6	6
28	Localization of the primary tumor (LPT) and maintenance strategies after first line oxaliplatin (Ox), fluoropyrimidine (FP), and bevacizumab (Bev) in metastatic colorectal cancer (mCRC): Results from the AIO 0207 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3543-3543.	1.6	4
29	Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis. <i>Brain Communications</i> , 2021, 3, fcb238.	3.3	4
30	Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 648-648.	1.6	3
31	A phase 2 multicenter, open-label, randomized, controlled trial in patients with stage II/III colorectal cancer who are ctDNA positive following resection to compare efficacy of autogene cevumeran versus watchful waiting.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3641-TPS3641.	1.6	3
32	ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumors An explorative randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4150-TPS4150.	1.6	2
33	Serial analysis of mutant KRAS in circulation cell-free DNA (cfDNA) of patients with KRAS mutant metastatic colorectal cancer: A translational study of the KRK0207 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15599-e15599.	1.6	2
34	Association of microsatellite instability with distinct clinical and molecular characteristics in resected colon cancer: Analysis of a platform trial of the AIO colorectal study group Colopredict Plus.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15086-e15086.	1.6	2
35	Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 811291.	2.3	2
36	Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KRK-0212.) <i>Journal of Clinical Oncology</i> , 2022, 40, 3536-3536.	1.6	2

#	ARTICLE	IF	CITATIONS
37	BRAF-mutant metastatic colorectal cancer: Prognostic and predictive value of primary tumor location. A pooled analysis of the AIO studies FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI. Journal of Clinical Oncology, 2022, 40, 3576-3576.	1.6	2
38	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC). Journal of Clinical Oncology, 2021, 39, 412-412.	1.6	1
39	Association of high microsatellite instability (MSI-H) with a high immunoscore (IS) compared to PD-L1 expression and increased survival in patients (pts) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (Ox) and fluoropyrimidine (FP): A pooled analysis of the AIO KRK 0207 and RO91 trials. Journal of Clinical Oncology, 2017, 35, 3595-3595.	1.6	1
40	Efficacy of gemcitabine with erlotinib in rash-positive patients selected according to eligibility for FOLFIRINOX. Journal of Clinical Oncology, 2017, 35, 4108-4108.	1.6	1
41	Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P). Journal of Clinical Oncology, 2020, 38, 750-750.	1.6	1
42	Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy. Cancers, 2022, 14, 526.	3.7	1
43	Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab. Journal of Clinical Oncology, 2016, 34, 3551-3551.	1.6	0
44	A blood-based assay for diagnosis of early-stage pancreatic cancer. Journal of Clinical Oncology, 2019, 37, 234-234.	1.6	0
45	Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI. A randomized, open label, phase-2 study (AIO) Tj ETQq1 1 0.784314 rgBT /Over	1.6	0
46	Correlation of histopathologic regression with progression free survival (PFS) in patients (pts) with RAS wildtype metastatic colorectal cancer (mCRC) under fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone: Subgroup analysis of VOLFI (AIO-KRK-0109). Journal of Clinical Oncology, 2019, 37, e15024-e15024.	1.6	0
47	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC). Journal of Clinical Oncology, 2020, 38, e16800-e16800.	1.6	0
48	Implementing a novel method to estimate the "Burden of Therapy" (BOTH) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial. Journal of Clinical Oncology, 2020, 38, e16786-e16786.	1.6	0
49	Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial. Journal of Clinical Oncology, 2020, 38, 686-686.	1.6	0
50	Label-free and automated approach to rapidly classify microsatellite instability (MSI) in early colon cancer (CC) analyzing the AIO ColoPredictPlus 2.0 (CPP) registry trial. Journal of Clinical Oncology, 2022, 40, 3616-3616.	1.6	0
51	Attitude towards and experience with SARS-CoV-2 vaccination among German cancer patients. Journal of Clinical Oncology, 2022, 40, e18603-e18603.	1.6	0
52	Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212). Journal of Clinical Oncology, 2022, 40, 3567-3567.	1.6	0
53	Geriatric assessment (GA) and the influence on the variability of treatment recommendations for elderly patients (pts) with gastrointestinal (GI) tumors. Journal of Clinical Oncology, 2022, 40, 12049-12049.	1.6	0
54	Impact of the COVID-19 pandemic on colorectal cancer (CRC) care: Data from 22 German cancer centers (CC) and the Institute of Pathology, Ruhr-University Bochum - the AIO (Working Group for Internal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Clinical Oncology, 2022, 40, 3626-3626.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab-FOLFOX induction in <i>RAS</i> wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212).. Journal of Clinical Oncology, 2022, 40, 3537-3537.	1.6	0